Developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection. By leveraging the natural power of the immune response system, we are able to utilize fusion protein technology to attack difficult tumor targets throughout the body.
Companies with Curative Ambition
Breakthrough is Just the Beginning for Our Entrepreneurs
Meet a Member of
Our Family Tree
Dr. Milenko Cicmil, CEO of Tasca Therapeutics
As a veteran in the world of drug discovery, the beginnings of my partnership with Cure Ventures and the building of Tasca Therapeutics can be linked back to a single walk in the park with one of the founding partners, Dave Fallace.
Cure Portfolio Companies
Loading...
With a novel approach to precision oncology, Tasca Therapeutics is unlocking post-translational modification of proteins by utilizing our state-of-the-art chemical biology and computational approaches, and combining with inhibition at key metabolic nodes to generate drugs for previously considered undruggable targets. Tasca is focused on using its proprietary platform to develop small molecule drugs for hard-to-treat oncology indications.
Advancing off-the-shelf dopamine neuron replacement therapies as a disease-modifying and potentially curative treatment for neurological disorders. Our proprietary platform leverages a novel approach to treating central nervous system disorders, such as Parkinson’s disease, by replacing neurons lost due to neurodegeneration.
Stealth Mode Newco – microRNA Therapeutics Company
Stealth Mode Newco – New Therapeutic Leads From Exercise Stimulated Muscle Company
Stealth Mode Newco – Condition-Specific Biologic Therapeutics Company
Stealth Mode Newco – Nonviral Delivery Platform Company
Undisclosed – Revenue Stage Digital Health Company
End of content
No more pages to load